Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mutlu Hizal

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Cancer|October 4, 2025
Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL studySafa Can Efil, Sema Nur Ozsan Celebi, Beste Ozturk, et al.
Journal of Cancer Research and Therapeutics|April 3, 2023
Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectationsSeda Kahraman, Murat Bardakci, Musa B Aykan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2020
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)Mutlu Hizal, Mehmet An Sendur, Hatime Arzu Yasar, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.
Journal of Cancer Research and Clinical Oncology|July 31, 2021
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group StudyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
BMC Cancer|November 22, 2025
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access programMehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar, et al.
BMC Cancer|December 30, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studySeda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Cancer|October 4, 2025
Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL studySafa Can Efil, Sema Nur Ozsan Celebi, Beste Ozturk, et al.
Journal of Cancer Research and Therapeutics|April 3, 2023
Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectationsSeda Kahraman, Murat Bardakci, Musa B Aykan, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2020
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)Mutlu Hizal, Mehmet An Sendur, Hatime Arzu Yasar, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.
Journal of Cancer Research and Clinical Oncology|July 31, 2021
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group StudyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
BMC Cancer|November 22, 2025
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access programMehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar, et al.
BMC Cancer|December 30, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studySeda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Pageof 3